Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

Collaboration › Details

Editas Medicine–Chardan: investor conference, 201910 supply service Editas participates in Chardan Genetic Medicines Conference in New York

	Period	2019-10-07 ï¿½ 2019-10-08
	Region	New York, NY
	Country	United States (USA)
	Partner, 1st	Editas Medicine Inc. (Nasdaq: EDIT)
	Partner, 2nd	Chardan Capital Markets LLC
	Product	Chardan Genetic Medicines Conference 2019 New York
	Product 2	CRISPR gene editing technology
	Source	Editas Medicine, Inc.. (8/6/19). "Press Release: Editas Medicine Announces Second Quarter 2019 Results and Update". Cambridge, MA.

Record changed: 2019-09-02

More documents for Editas Medicine Inc. (Nasdaq: EDIT)

[1] Editas Medicine, Inc.. (7/7/20). "Press Release: Editas Medicine and Azzur Group Announce a Multi-year Agreement for EDIT-301 and EDIT-201 Manufacturing". Cambridge, MA & Waltham, MA....
[2] Editas Medicine, Inc.. (6/26/20). "Press Release: Editas Medicine Announces Closing of Offering of Common Stock and Full Exercise by Underwriter of Option to Purchase Additional Shares". Cambridge, MA....
[3] Editas Medicine, Inc.. (6/23/20). "Press Release: Editas Medicine Announces Pricing of Offering of Common Stock". Cambridge, MA....
[4] Editas Medicine, Inc.. (6/23/20). "Press Release: Editas Medicine Announces Offering of Common Stock". Cambridge, MA....
[5] Editas Medicine, Inc.. (6/12/20). "Press Release: Editas Medicine Presents Pre-Clinical Data from a Study of EDIT-301 with Sickle Patient Cells for the Potential Treatment of Sickle Cell Disease". Cambridge, MA....
[6] Editas Medicine, Inc.. (5/15/20). "Press Release: Editas Medicine Presents Pre-Clinical Data Supporting the Use of CRISPR-Cas12a to Edit Induced Pluripotent Stem Cells for the Development of Engineered Cell Immunotherapies". Cambridge, MA....
[7] Editas Medicine, Inc.. (5/7/20). "Press Release: Editas Medicine Announces First Quarter 2020 Results and Update". Cambridge, MA....
[8] Editas Medicine, Inc.. (4/29/20). "Press Release: Editas Medicine Initiates IND-enabling Activities for EDIT-201, an Allogeneic NK Cell Medicine for the Treatment of Solid Tumor Cancers". Cambridge, MA....
[9] Editas Medicine, Inc.. (2/26/20). "Press Release: Editas Medicine Announces Fourth Quarter and Full Year 2019 Results and Update". Cambridge, MA....
[10] Editas Medicine, Inc.. (1/9/20). "Press Release: Editas Medicine Strengthens Executive Leadership Team to Support Long-term Growth. Michelle Robertson Joins as Chief Financial Officer". Cambridge, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]